{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:30:07Z","timestamp":1759177807176,"version":"3.41.0"},"reference-count":69,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Venous thromboembolism (VTE) is the third most common acute cardiovascular syndrome after acute myocardial infarction and stroke. In recent years, there has been an increase in the incidence of VTE, related to population aging and common comorbidities in the elderly, including chronic cardiorespiratory disease and cancer. On the other hand, disease-related mortality, particularly for pulmonary embolism (PE), shows a decreasing trend, which can be explained by improvements in diagnostic imaging, advances in available therapies, and greater adherence to patient management protocols. The guidelines presented here provide recommendations for the pharmacological treatment of PE in Brazil, on the basis of scientific evidence and with a focus on common practical issues. Six Patient, Intervention, Comparison, and Outcome questions were developed by a group of experts on the topic. Systematic reviews of randomized clinical trials were conducted for each question, with meta-analyses being performed when possible. The level of evidence and strength of recommendation were defined in accordance with the Grading of Recommendations Assessment, Development, and Evaluation approach. With these guidelines, we expect to provide relevant, up-to-date information on the pharmacological treatment of PE.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20240314","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:11:36Z","timestamp":1748272296000},"page":"e20240314","source":"Crossref","is-referenced-by-count":1,"title":["Brazilian guidelines for the pharmacological treatment of pulmonary embolism. Official document of the Brazilian Thoracic Association based on the GRADE methodology"],"prefix":"10.36416","author":[{"given":"Veronica","family":"Moreira Amado1","sequence":"first","affiliation":[{"name":"1. Universidade de Bras\u00edlia \u2013 UnB \u2013 Bras\u00edlia (DF) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio","family":"J\u00falio C\u00e9sar dos Santos Fernandes2","sequence":"additional","affiliation":[{"name":"2. Grupo de Circula\u00e7\u00e3o Pulmonar, Departamento de Cardiopneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Salibe-Filho2","sequence":"additional","affiliation":[{"name":"2. Grupo de Circula\u00e7\u00e3o Pulmonar, Departamento de Cardiopneumologia, Instituto do Cora\u00e7\u00e3o, Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Basso Gazzana3","sequence":"additional","affiliation":[{"name":"3. Universidade Federal do Rio Grande do Sul \u2013 UFRGS \u2013 Porto Alegre (RS) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Thereza Rocha4","sequence":"additional","affiliation":[{"name":"4. Departamento de Sa\u00fade da Fam\u00edlia, Universidade Federal da Bahia \u2013 UFBA \u2013 Salvador (BA) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Hyung Bok Yoo5","sequence":"additional","affiliation":[{"name":"5. Faculdade de Medicina de Botucatu, Universidade Estadual Paulista \u2013 UNESP \u2013 Botucatu (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanderley","family":"Marques Bernardo6,7","sequence":"additional","affiliation":[{"name":"6. Programa de Diretrizes, Associa\u00e7\u00e3o M\u00e9dica Brasileira, S\u00e3o Paulo (SP) Brasil. 7. Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"Tanni5","sequence":"additional","affiliation":[{"name":"5. Faculdade de Medicina de Botucatu, Universidade Estadual Paulista \u2013 UNESP \u2013 Botucatu (SP) Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.           Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort. Am J Med. 2013;126(9):832. https:\/\/doi.org\/10.1016\/j.amjmed.2013.02.024","DOI":"10.1016\/j.amjmed.2013.02.024"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.           Jim\u00e9nez D, de Miguel-D\u00edez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, et al. Trends in the Management and Outcomes of Acute Pulmonary Embolism. J Am Coll Cardiol. 2016;67(2):162-70. https:\/\/doi.org\/10.1016\/j.jacc.2015.10.060","DOI":"10.1016\/j.jacc.2015.10.060"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.           Gomes JA, Barros JEB, Nascimento ALOD, Rocha CAO, Almeida JPO, Santana GBA, et al. Hospitalizations for pulmonary embolism in Brazil (2008-2019): an ecological and time series study. J Bras Pneumol. 2022;48(3):e20210434. https:\/\/doi.org\/10.36416\/1806-3756\/e20210434","DOI":"10.36416\/1806-3756\/e20210434"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.           Terra-Filho M, Menna-Barreto SS; Comiss\u00e3o de Circula\u00e7\u00e3o Pulmonar da SBPT. Recomenda\u00e7\u00f5es para o manejo da tromboembolia pulmonar, 2010. J Br\u00e1s Pneumol. 2010;36(Suppl 1):S1-S68.","DOI":"10.1590\/s1806-37132010001300001"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","DOI":"10.1136\/bmj.39489.470347.ad"},{"key":"ref5","unstructured":"6.           Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A editors. GRADE handbook for grading quality of evidence and strength of recommendations [monograph on the Internet]. Hamilton, ON: GRADEpro; 2013. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.           Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","DOI":"10.1136\/bmj.b2535"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ; et al. What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ. 2008;336(7651):995-8. https:\/\/doi.org\/10.1136\/bmj.39490.551019.BE","DOI":"10.1136\/bmj.39490.551019.be"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.           Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049-51. https:\/\/doi.org\/10.1136\/bmj.39493.646875.AE","DOI":"10.1136\/bmj.39493.646875.ae"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.        Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos, Departamento de Ci\u00eancia e Tecnologia. Diretrizes metodol\u00f3gicas: Sistema GRADE \u2013 Manual de gradua\u00e7\u00e3o da qualidade da evid\u00eancia e for\u00e7a de recomenda\u00e7\u00e3o para tomada de decis\u00e3o em sa\u00fade. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2014.","DOI":"10.1590\/s0102-311x2008001400021"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.        Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54(3):1901647. https:\/\/doi.org\/10.1183\/13993003.01647-2019","DOI":"10.1183\/13993003.01647-2019"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.        Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an  international, open-label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41-8. https:\/\/doi.org\/10.1016\/S0140-6736(11)60824-6","DOI":"10.1016\/s0140-6736(11)60824-6"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.        Frank Peacock W, Coleman CI, Diercks DB, Francis S, Kabrhel C, Keay C, et al. Emergency Department Discharge of Pulmonary Embolus Patients. Acad Emerg Med. 2018;25(9):995-1003. https:\/\/doi.org\/10.1111\/acem.13451","DOI":"10.1111\/acem.13451"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.        Den Exter PL, Zondag W, Klok FA, Brouwer RE, Dolsma J, Eijsvoge M, et al. Efficacy and safety of outpatient treatment based on the hestia clinical decision rule with or without N-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism: A randomized clinical trial. Am J Respir Crit Care Med. 2016;194(8):998-1006. https:\/\/doi.org\/10.1164\/rccm.201512-2494OC","DOI":"10.1164\/rccm.201512-2494oc"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.        Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009;361(24):2342-52. https:\/\/doi.org\/10.1056\/NEJMoa0906598","DOI":"10.1056\/nejmoa0906598"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.        Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2013;368(8):699-708. https:\/\/doi.org\/10.1056\/NEJMoa1207541","DOI":"10.1056\/nejmoa1207541"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.        Hokusai-VTE Investigators; B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013;369(15):1406-15. https:\/\/doi.org\/10.1056\/NEJMoa1306638","DOI":"10.1056\/nejmoa1306638"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.        Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-8. https:\/\/doi.org\/10.1182\/blood-2002-01-0108","DOI":"10.1182\/blood-2002-01-0108"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.        McBane Ii R, Loprinzi CL, Ashrani A, Perez-Botero J, Leon Ferre RA, Henkin S, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: The ADAM VTE trial. Thromb Haemost. 2017;117(10):1952-1961.  https:\/\/doi.org\/10.1160\/TH17-03-0193","DOI":"10.1160\/th17-03-0193"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.        Agnelli G, Mu\u00f1oz A, Franco L, Mah\u00e9 I, Brenner B, Connors JM, et al. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. J Thromb Haemost. 2022;122(5):796-807. https:\/\/doi.org\/10.1055\/s-0041-1735194","DOI":"10.1055\/s-0041-1735194"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.        Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mah\u00e9 I, et al. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. Chest. 2022;161(3):781-790. https:\/\/doi.org\/10.1016\/j.chest.2021.09.037","DOI":"10.1016\/s0049-3848(21)00159-6"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.        Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-23. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034","DOI":"10.1200\/jco.2018.78.8034"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.        Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3(8):e379-87. https:\/\/doi.org\/10.1016\/S2352-3026(16)30057-6","DOI":"10.1016\/s2352-3026(16)30057-6"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.        Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, et al. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients with Cancer: A Randomized Clinical Trial. JAMA. 2023;329(22):1924-1933. https:\/\/doi.org\/10.1001\/jama.2023.7843","DOI":"10.1001\/jama.2023.7843"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.        Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129-37. https:\/\/doi.org\/10.4137\/CMO.S18991","DOI":"10.4137\/cmo.s18991"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.        Laporte S, Mismetti P, D\u00e9cousus H, Uresandi F, Otero R, Lobo JL, et al. Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism: Findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry. Circulation. 2008;117(13):1711-6. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.726232","DOI":"10.1161\/circulationaha.107.726232"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.        Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14. https:\/\/doi.org\/10.1007\/s11239-015-1311-6","DOI":"10.1007\/s11239-015-1311-6"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.        Martins MA, Silva TF, Fernandes CJ. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism. Curr Oncol Rep. 2023;25(5):425-32. https:\/\/doi.org\/10.1007\/s11912-023-01384-7","DOI":"10.1007\/s11912-023-01384-7"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.        Fernandes CJ, Morinaga LTK, Alves JL, Castro MA, Calderaro D, Jardim CVP, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151):180119. https:\/\/doi.org\/10.1183\/16000617.0119-2018","DOI":"10.1183\/16000617.0119-2018"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30.        Fernandes CJ, Alves J\u00fanior JL, Gavilanes F, Prada LF, Morinaga LK, Souza R. New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol. 2016;42(2):146-154. https:\/\/doi.org\/10.1590\/S1806-37562016042020068","DOI":"10.1590\/s1806-37562016042020068"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.        Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.  https:\/\/doi.org\/10.1056\/NEJMoa025313","DOI":"10.1056\/nejmoa025313"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.        Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-52. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.        Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN Study. J Thromb Haemost. 2015;13(6):1028-1035. https:\/\/doi.org\/10.1111\/jth.12923","DOI":"10.1111\/jth.12923"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.        Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Eng J Med. 2018;378(7):615-24. https:\/\/doi.org\/10.1056\/NEJMoa1711948","DOI":"10.1016\/j.jvsv.2019.04.004"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.        Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman M V., Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Eng J Med. 2020;382(17):1599-607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","DOI":"10.1056\/nejmoa1915103"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.        Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. N Eng J Med. 2013;368(8):709-18. https:\/\/doi.org\/10.1056\/NEJMoa1113697","DOI":"10.1056\/nejmoa1113697"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.        Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S-69S. https:\/\/doi.org\/10.1016\/S0735-1097(02)02776-6","DOI":"10.1016\/S0735-1097(02)02776-6"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.        Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. N Eng J Med. 1999;340(12):901-7. https:\/\/doi.org\/10.1056\/NEJM199903253401201","DOI":"10.1056\/nejm199903253401201"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39.        Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE randomized clinical trial. JAMA. 2015;314(1):31-40. https:\/\/doi.org\/10.1001\/jama.2015.7046","DOI":"10.1016\/j.jvs.2015.10.017"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40.        Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Eng J Med. 2017;376(13):1211-22. https:\/\/doi.org\/10.1056\/NEJMoa1700518","DOI":"10.1016\/j.jvsv.2017.06.006"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.        Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):2247-59. https:\/\/doi.org\/10.1016\/j.chest.2021.07.056","DOI":"10.1016\/j.chest.2021.07.055"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.        Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Eng J Med. 2018;378(21):2010-21. https:\/\/doi.org\/10.1056\/NEJMra1705454","DOI":"10.1056\/NEJMra1705454"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.        Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-71. https:\/\/doi.org\/10.1182\/blood-2018-04-848333","DOI":"10.1182\/blood-2018-04-848333"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.        Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559","DOI":"10.1161\/jaha.120.017559"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45.        Goldhaber SZ, Schellong S, Kakkar A, Eriksson H, Feuring M, Kreuzer J, et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. J Thromb Haemost. 2016;116(4):714-21. https:\/\/doi.org\/10.1160\/TH16-04-0271","DOI":"10.1160\/th16-04-0271"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.        EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med. 2010;363(26):2499-510. https:\/\/doi.org\/10.1056\/NEJMoa1007903","DOI":"10.1056\/nejmoa1007903"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.        Bailey AL. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Cardiol Rev. 2012;28:1287.","DOI":"10.1056\/NEJMoa1113572"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.        Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. Zeitschrift fur Gefassmedizin. 2013;10:25.","DOI":"10.1056\/NEJMoa1302507"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49.        Elshafei MN, Mohamed MFH, El-Bardissy A, Ahmed MB, Abdallah I, Elewa H, et al. Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. J Thromb Thrombolysis. 2021;51(2):388-96. https:\/\/doi.org\/10.1007\/s11239-020-02179-4","DOI":"10.1007\/s11239-020-02179-4"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50.        Su X, Yan B, Wang L, Cheng H, Chen Y. Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: A systematic review, pairwise and network meta-analysis. BMJ Open. 2022;12(2):e048619. https:\/\/doi.org\/10.1136\/bmjopen-2021-048619","DOI":"10.1136\/bmjopen-2021-048619"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51.        Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)[see comment]. Lancet. 1999;353(9162):1386-9. https:\/\/doi.org\/10.1016\/S0140-6736(98)07534-5","DOI":"10.1016\/s0140-6736(98)07534-5"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52.        Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000;101(24):2817-22. https:\/\/doi.org\/10.1161\/01.CIR.101.24.2817","DOI":"10.1161\/01.cir.101.24.2817"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53.        Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143-50. https:\/\/doi.org\/10.1056\/NEJMoa021274","DOI":"10.1056\/nejmoa021274"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54.        Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: Comparison of thrombolysis with heparin. Am J Med Sci. 2011;341(1):33-9. https:\/\/doi.org\/10.1097\/MAJ.0b013e3181f1fc3e","DOI":"10.1097\/maj.0b013e3181f1fc3e"},{"key":"ref54","unstructured":"55.        Taherkhani M, Taherkhani A, Hashemi SR, Faghihi Langroodi T, Sadeghi R, Beyranvand M. Thrombolytic-plus-Anticoagulant Therapy versus Anticoagulant-Alone Therapy in Submassive Pulmonary Thromboembolism (TVASPE Study): A Randomized Clinical Trial. J Tehran Heart Cent. 2014;9(3):104-108."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56.        Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12(4):459-68. https:\/\/doi.org\/10.1111\/jth.12521","DOI":"10.1111\/jth.12521"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57.        Sinha SK, Sachan M, Goel A, Singh K, Mishra V, Jha MJ, et al. Efficacy and Safety of Thrombolytic Therapy in Acute Submassive Pulmonary Embolism: Follow-Up Study. J Clin Med Res. 2017;9(2):163-9. https:\/\/doi.org\/10.14740\/jocmr2829w","DOI":"10.14740\/jocmr2829w"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"58.        Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med. 2014;370(15):1402-11. https:\/\/doi.org\/10.1056\/NEJMoa1302097","DOI":"10.1056\/nejmoa1302097"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"59.        Konstantinides SV, Meyer G, Vicaut E. Impact of thrombolytic therapy on the long-term outcome of patients with intermediate-risk pulmonary embolism: Results of the large multicentre pulmonary embolism thrombolysis (PEITHO) trial. Eur Heart J. 2016;37:406. Available from: https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L612285244&from=export","DOI":"10.3410\/f.727444534.793534198"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60.        Falster C, Jacobsen N, Coman KE, H\u00f8jlund M, Gaist TA, Posth S, et al. Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis. Thorax. 2022;77(7):679-89. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-216838","DOI":"10.1136\/thoraxjnl-2021-216838"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61.        Leidi A, Bex S, Righini M, Berner A, Grosgurin O, Marti C. Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives. J Clin Med. 2022;11(9):2533. https:\/\/doi.org\/10.3390\/jcm11092533","DOI":"10.3390\/jcm11092533"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.        Zhang Z, Zhai ZG, Liang LR, Liu FF, Yang YH, Wang C. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysis. Thromb Res. 2014;133(3):357-63. https:\/\/doi.org\/10.1016\/j.thromres.2013.12.026","DOI":"10.1016\/j.thromres.2013.12.026"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63.        Harvey JJ, Huang S, Uberoi R. Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism. Cochrane Database Syst Rev. 2022;8(8):CD013083. https:\/\/doi.org\/10.1002\/14651858.CD013083.pub2","DOI":"10.1002\/14651858.cd013083.pub2"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64.        Sanchez O, Charles-Nelson A, Ageno W, Barco S, Binder H, Chatellier G, et al. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary  Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. J Thromb Haemost. 2022;122(5):857-66. https:\/\/doi.org\/10.1055\/a-1653-4699","DOI":"10.1055\/a-1653-4699"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65.        Mathew D, Kim J, Kosuru BP, Devagudi D, Sherif A, Shrestha U, et al. Mortality and bleeding associated with the management of sub-massive pulmonary embolism: a systematic review and Bayesian network meta-analysis. Sci Rep. 2023;13(1):7169. https:\/\/doi.org\/10.1038\/s41598-023-34348-9","DOI":"10.1038\/s41598-023-34348-9"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"66.        Jerjes-Sanchez C, Ramirez-Rivera A, De M, Garcia L, Arriaga-Nava R, Valencia S, et al. Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. J Thromb Thrombolysis. 1995;2(3):227-229. https:\/\/doi.org\/10.1007\/BF01062714","DOI":"10.1007\/bf01062714"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67.        Goldhaber SZ, Come PC, Lee RT, Braunwald E, Parker JA, Haire WD, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844):507-11. https:\/\/doi.org\/10.1016\/0140-6736(93)90274-K","DOI":"10.1016\/0140-6736(93)90274-k"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"68.        Donz\u00e9 J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, et al. Prospective validation of the Pulmonary Embolism Severity Index: A clinical prognostic model for pulmonary embolism. J Thromb Haemost. 2008;100(5):943-8. https:\/\/doi.org\/10.1160\/TH08-05-0285","DOI":"10.1160\/th08-05-0285"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"69.        Jim\u00e9nez D, Aujesky D, Moores L, G\u00f3mez V, Luis Lobo J, Uresandi F, et al. Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism Arch Intern Med. 2010;170(15):1383-1389. https:\/\/doi.org\/10.1001\/archinternmed.2010.199","DOI":"10.1001\/archinternmed.2010.199"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:11:44Z","timestamp":1748272304000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4090\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":69,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20240314","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}